2023 Fiscal Year Final Research Report
Development and characterization of cancer-specific monoclonal antibodies against tumor-associated glycoproteins.
| Project/Area Number |
21K07168
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Kaneko Mika 東北大学, 医学系研究科, 准教授 (00323163)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 抗体創薬 / CasMab / 腫瘍特異的 |
|---|
| Outline of Final Research Achievements |
In this research project, we aimed to establish cancer-specific antibodies by targeting proteins expressed in both cancer cells and normal cells, for which antibody therapeutics have already been developed but superior antibodies are expected, or for novel targets where antibody therapeutics do not exist.
As part of the characterization of established cancer-specific antibodies, we verified their utility for various applications such as FACS, WB, IHC, etc., and elucidated epitopes responsible for tumor specificity.Furthermore, we validated the potential of cancer-specific antibodies for therapeutic development by assessing their anti-tumor effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
|
| Free Research Field |
抗体創薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
現在、がん治療の抗体医薬の標的分子は、がん細胞に発現している分子か、免疫チェックポイントに関与する分子が主である。がん細胞に発現している分子については、正常細胞にも発現しているものが多く、正常細胞上の標的分子は認識せずに、がん細胞上の標的分子のみを認識する抗体は、重大な副作用を避けられることが予想され、医薬品として非常に期待される。我々はがん細胞に特異的な反応性を示すモノクローナル抗体作製技術（CasMab法）を開発し、細胞表面に発現している膜タンパク質に対し、がん細胞のみを攻撃する抗体を作製することが可能となった。本研究により副作用の少ない抗体医薬や免疫療法の開発が可能になる。
|
